Citizens Financial Group Inc. RI Buys 201 Shares of Novo Nordisk A/S (NYSE:NVO)

Citizens Financial Group Inc. RI increased its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 1.5% in the first quarter, according to its most recent filing with the SEC. The fund owned 13,904 shares of the company’s stock after acquiring an additional 201 shares during the period. Citizens Financial Group Inc. RI’s holdings in Novo Nordisk A/S were worth $1,785,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of NVO. First PREMIER Bank purchased a new position in Novo Nordisk A/S during the 1st quarter worth $25,000. Dixon Mitchell Investment Counsel Inc. purchased a new position in Novo Nordisk A/S during the 1st quarter worth $26,000. Orion Capital Management LLC purchased a new position in Novo Nordisk A/S during the 1st quarter worth $26,000. CNB Bank acquired a new stake in Novo Nordisk A/S during the 4th quarter worth about $26,000. Finally, Redmont Wealth Advisors LLC acquired a new stake in Novo Nordisk A/S during the 1st quarter worth about $34,000. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Trading Down 3.8 %

NVO traded down $4.97 during trading hours on Friday, reaching $127.49. The company’s stock had a trading volume of 4,659,450 shares, compared to its average volume of 4,406,218. Novo Nordisk A/S has a fifty-two week low of $78.19 and a fifty-two week high of $148.15. The stock has a market cap of $572.12 billion, a PE ratio of 43.85, a P/E/G ratio of 1.33 and a beta of 0.41. The business’s 50-day moving average is $138.38 and its 200-day moving average is $128.90. The company has a debt-to-equity ratio of 0.17, a current ratio of 0.70 and a quick ratio of 0.50.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Thursday, May 2nd. The company reported $0.83 EPS for the quarter, beating analysts’ consensus estimates of $0.77 by $0.06. Novo Nordisk A/S had a return on equity of 91.70% and a net margin of 36.56%. The firm had revenue of $9.52 billion for the quarter, compared to analysts’ expectations of $9.23 billion. As a group, equities research analysts predict that Novo Nordisk A/S will post 3.38 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. BMO Capital Markets reissued an “outperform” rating and issued a $163.00 price objective on shares of Novo Nordisk A/S in a report on Tuesday, June 25th. The Goldman Sachs Group began coverage on Novo Nordisk A/S in a report on Thursday, May 30th. They issued a “buy” rating and a $156.00 price target for the company. Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Monday, July 1st. Finally, Argus boosted their price objective on Novo Nordisk A/S from $125.00 to $160.00 and gave the stock a “buy” rating in a research note on Monday, June 10th. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $145.67.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.